60 results
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
14 May 24
NeuroOne® Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
4:10pm
excellent progress this quarter across multiple fronts. Revenue growth continued regarding our sEEG product line as new customer sites were added … FDA 510(k) clearance to market this novel technology in the United States. Customer interest has been strong and we believe the OneRF™ Ablation
8-K
EX-99.1
NMTC
NeuroOne Medical Technologies Corp
13 Feb 24
NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
4:15pm
® sEEG:
Customer feedback remains positive as commercial launch expands with new accounts
Product exhibited at annual meeting of American Epilepsy … have a positive impact on Evo sEEG customer demand. Coupled with the progress on our drug delivery and spinal cord stimulation programs, we remain
8-K
EX-10.1
gpuq3wxmclkgdnp y9sl
14 Nov 23
Volker strengthens existing management team in areas of commercialization, business development, and reimbursement
5:28pm
424B5
0cxdqvhfzhawb3zp
26 Jul 23
Prospectus supplement for primary offering
4:24pm
424B5
aqr5scoib
24 Jul 23
Prospectus supplement for primary offering
4:43pm
424B5
n7e2l
22 Dec 22
Prospectus supplement for primary offering
6:43am
424B5
1nq1pupd51j4 qwhi
14 Oct 21
Prospectus supplement for primary offering
8:31am
424B5
7kua 86xi5ut34s8
13 Oct 21
Prospectus supplement for primary offering
12:00am